Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs. Denosumab is an inhibitor of RANKL (receptor activator of nuclear factor kappa-Î’ ligand), which works by decreasing the development of osteoclasts, which are cells that break down bone. It was developed by the biotechnology company Amgen.